Almajid Ali, Bazroon Ali, Albarbari Hassan, Al-Awami Hashim M, AlAhmed Alzahraa, Bakhurji Omar M, Alharbi Ghadah, Aldawood Fatemah, AlKhamis Zainab, Alqarni Mohammed, Alabdullah Mohammed, Almutairi Raghad
Department of Internal Medicine, King Fahad Specialist Hospital, Dammam, SAU.
Faculty of Medicine, King Abdulaziz University Hospital, Jeddah, SAU.
Cureus. 2023 Dec 31;15(12):e51385. doi: 10.7759/cureus.51385. eCollection 2023 Dec.
Background Antimicrobial resistance (AMR) has been designated a public health crisis by the World Health Organization. AMR can lead to escalated healthcare costs, higher mortality rates, increased morbidity, and more frequent hospitalizations. This study aimed to retrospectively evaluate the appropriateness of Tazocin prescription for community-acquired pneumonia (CAP). Methodology We conducted a retrospective analysis of patients aged ≥18 years who were admitted with a diagnosis of CAP and administered intravenous Tazocin between November 2021 and October 2022. The primary objective was to assess the appropriateness of Tazocin prescriptions in patients with CAP. Results A total of 39 patients with CAP were included, with a mean age of 61 ± 17.36 years. Overall, 24 (61%) patients were male. The rate of inappropriate prescriptions of Tazocin was 66.6%. The incidence of inappropriate Tazocin prescription varied significantly among different medical specialties, with the highest rate observed in the oncology-palliative specialty (90%; p = 0.033). Conclusions Our study affirms the inclination of physicians to prescribe Tazocin for CAP without justifiable indications and highlights the unwarranted use of Tazocin for CAP across various medical specialties. This is evidenced by the notably high rate of inappropriate empirical prescriptions.
背景 抗菌药物耐药性（AMR）已被世界卫生组织认定为一场公共卫生危机。抗菌药物耐药性可导致医疗成本上升、死亡率升高、发病率增加以及住院频率提高。本研究旨在回顾性评估哌拉西林他唑巴坦用于社区获得性肺炎（CAP）的处方合理性。方法 我们对2021年11月至2022年10月期间因CAP诊断入院并接受静脉注射哌拉西林他唑巴坦的≥18岁患者进行了回顾性分析。主要目的是评估CAP患者中哌拉西林他唑巴坦处方的合理性。结果 共纳入39例CAP患者，平均年龄为61±17.36岁。总体而言，24例（61%）患者为男性。哌拉西林他唑巴坦不适当处方率为66.6%。不同医学专科中哌拉西林他唑巴坦不适当处方的发生率差异显著，肿瘤姑息专科的发生率最高（90%；p = 0.033）。结论 我们的研究证实了医生在无合理指征的情况下为CAP开具哌拉西林他唑巴坦的倾向，并凸显了在各个医学专科中对CAP不合理使用哌拉西林他唑巴坦的情况。这一点在不适当经验性处方的显著高发生率中得到了证明。
